Pembrolizumab,MK-4830,Belzutifan,Lenvatinib,Quavonlimab,Favezelimab
Eisai,Merck
['lenva', 'renal,(-adrenal)', 'belzutifan']
belzutifan plus lenvatinib elicited promising antitumor activity with a manageable safety profile as a second-line or later treatment for renal cell carcinoma. #asco23 #urology #urologist #kidneycancer
The Leading News Source for Urologists - https://t.co/hDKngB4IyE
Expert clinical analysis. Practice advice. Policy perspectives.